ACADIA Pharmaceuticals/$ACAD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Ticker
$ACAD
Sector
Primary listing
Employees
654
Headquarters
Website
ACAD Metrics
BasicAdvanced
$3.7B
14.05
$1.54
0.68
-
Price and volume
Market cap
$3.7B
Beta
0.68
52-week high
$26.65
52-week low
$13.40
Average daily volume
2M
Financial strength
Current ratio
3.019
Quick ratio
2.766
Long term debt to equity
4.691
Total debt to equity
4.691
Profitability
EBITDA (TTM)
108.427
Gross margin (TTM)
62.91%
Net profit margin (TTM)
24.94%
Operating margin (TTM)
9.02%
Effective tax rate (TTM)
4.57%
Revenue per employee (TTM)
$1,600,000
Management effectiveness
Return on assets (TTM)
5.11%
Return on equity (TTM)
34.95%
Valuation
Price to earnings (TTM)
14.047
Price to revenue (TTM)
3.463
Price to book
3.98
Price to tangible book (TTM)
4.54
Growth
Revenue change (TTM)
12.69%
Earnings per share change (TTM)
98.53%
3-year revenue growth (CAGR)
26.97%
10-year revenue growth (CAGR)
154.46%
3-year earnings per share growth (CAGR)
4.72%
10-year earnings per share growth (CAGR)
0.44%
What the Analysts think about ACAD
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
ACAD Financial Performance
Revenues and expenses
ACAD Earnings Performance
Company profitability
ACAD News
AllArticlesVideos
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
Business Wire2 weeks ago
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
Business Wire3 weeks ago
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals (ACAD) has a market cap of $3.7B as of November 07, 2025.
What is the P/E ratio for ACADIA Pharmaceuticals stock?
The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 14.05 as of November 07, 2025.
Does ACADIA Pharmaceuticals stock pay dividends?
No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next ACADIA Pharmaceuticals dividend payment date?
ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.
What is the beta indicator for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.